Icon Plc (NASDAQ:ICLR) Given Consensus Rating of "Moderate Buy" by Brokerages

Icon Plc (NASDAQ:ICLR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eighteen analysts that are currently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $219.6429.

Several research analysts have recently issued reports on ICLR shares. Evercore ISI upped their target price on shares of Icon from $170.00 to $240.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Citigroup restated a "neutral" rating and issued a $200.00 target price (down previously from $225.00) on shares of Icon in a report on Thursday, August 21st. Mizuho upped their target price on shares of Icon from $173.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Robert W. Baird upped their price target on shares of Icon from $222.00 to $224.00 and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Finally, Baird R W upgraded shares of Icon from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 24th.

Icon Trading Up 1.7%

NASDAQ ICLR opened at $177.81 on Tuesday. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35. Icon has a 52 week low of $125.10 and a 52 week high of $310.54. The stock has a market capitalization of $14.36 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.59 and a beta of 1.20. The firm has a 50 day moving average of $166.18 and a two-hundred day moving average of $158.16.

Icon (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.08. Icon had a net margin of 9.82% and a return on equity of 10.95%. The business had revenue of $2.02 billion during the quarter, compared to analysts' expectations of $1.98 billion. During the same quarter in the prior year, the business posted $3.75 EPS. The company's revenue for the quarter was down 4.8% on a year-over-year basis. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. As a group, research analysts expect that Icon will post 13.38 EPS for the current fiscal year.

Institutional Trading of Icon

Institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC raised its position in Icon by 22.8% in the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock valued at $99,000 after purchasing an additional 110 shares during the last quarter. NBC Securities Inc. purchased a new stake in Icon in the 1st quarter valued at $59,000. Wealthquest Corp purchased a new position in Icon during the 1st quarter worth $862,000. Arkadios Wealth Advisors raised its position in Icon by 573.7% during the 1st quarter. Arkadios Wealth Advisors now owns 7,828 shares of the medical research company's stock worth $1,370,000 after buying an additional 6,666 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Icon by 15,701.6% during the 1st quarter. GAMMA Investing LLC now owns 68,421 shares of the medical research company's stock worth $119,730,000 after buying an additional 67,988 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company's stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.